Genfit : VS-01 results now expected in H2 2025
>Iqirvo launch moving ahead “as expected” - Ahead of the AASLD congress to be held from 15 to 19 November, Genfit provided an update on the advances under way in its portfolio, both commercial and clinical.Firstly, the terms used to qualify the launch of Iqirvo by Ipsen (Genfit partner) are encouraging, as they underline positive commercial and regulatory developments, whether in the US or Europe. Moreover, the initial sales reimbursed in Germany and the reimburs...Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.